Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Gains from Sales and Divestitures: 2022-2024

Historic Gains from Sales and Divestitures for Organogenesis Holdings (ORGO) over the last 3 years, with Dec 2024 value amounting to $1.4 million.

  • Organogenesis Holdings' Gains from Sales and Divestitures rose 10.67% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year increase of 10.67%. This contributed to the annual value of $1.4 million for FY2024, which is 174.53% up from last year.
  • Latest data reveals that Organogenesis Holdings reported Gains from Sales and Divestitures of $1.4 million as of FY2024, which was up 174.53% from $522,651 recorded in FY2023.
  • In the past 5 years, Organogenesis Holdings' Gains from Sales and Divestitures registered a high of $1.4 million during FY2024, and its lowest value of $249,106 during FY2022.
  • For the 3-year period, Organogenesis Holdings' Gains from Sales and Divestitures averaged around $735,522, with its median value being $522,651 (2023).
  • Data for Organogenesis Holdings' Gains from Sales and Divestitures shows a peak YoY surged of 174.53% (in 2024) over the last 5 years.
  • Over the past 3 years, Organogenesis Holdings' Gains from Sales and Divestitures (Yearly) stood at $249,106 in 2022, then skyrocketed by 109.81% to $522,651 in 2023, then spiked by 174.53% to $1.4 million in 2024.